U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C.  20549
                          -----------------------------
                                   FORM 10-KSB
(Mark one)
[X]  Annual report under section 13 or 15(d) of the Securities Exchange Act of
     1934 For the fiscal year ended September 30, 2002

                                       OR
[ ]  Transition report under section 13 or 15(d) of the Securities Exchange Act
     of 1934

      For the transition Period from ________________ to ________________


                        Commission file number:  0-30096
                                                 -------

                            Duro Enzyme Products Inc.
                          -----------------------------
                 (Name of small business issuer in its charter)

                  Nevada                                     77-0454933
        -------------------------                           ------------
      (State or other jurisdiction of                          (I.R.S.
      incorporation or organization)                Employer Identification No.)

           20436 Fraser Highway
        Langley, British Columbia                             V3A 4G2
        -------------------------                           ------------
 (Address of principal executive offices)                    (Zip Code)

                  Issuer's telephone number: (604) 514 - 3044

Securities registered under Section 12(b) of the Act:
              (Title of Class)                         Name of exchange on which
                                                               registered

                   None                                           None
             ----------------                               ----------------

Securities  registered  under  Section  12(g) of the Act:   Common Stock,
                                                            $0.001 par value
                                                            ----------------
                                                            (Title of class)

Check  whether  the Issuer (1) filed all reports required to be filed by Section
13  or  15(d)  of  the Securities Exchange Act during the past 12 months (or for
such  shorter period that the registrant was required to file such reports), and
(2) has  been  subject to such filing requirements for the past 90 days. Yes  X
No                                                                           ---
   ---

Check  if there is no disclosure of delinquent filers in response to Item 405 of
Regulation  S-B  is  not  contained  in  this  form,  and  no disclosure will be
contained,  to  the  best  of  registrant's  knowledge,  in  definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or  any  amendment  to  this  Form  10-KSB. [ ]

Registrant's  revenues  for  its  most  recent  fiscal  year:  $Nil
                                                               ----

As  of December 10, 2002, the aggregate market value of the voting common equity
held  by  non-affiliates  of the registrant was $3,517,112, based on the closing
trade  reported  on  the NASD Over-the-Counter Bulletin Board National Quotation
System.  Shares  of  common  stock held by each officer and director and by each
person  who  owns five percent or more of the outstanding common stock have been
excluded  from  this  calculation  as  such  persons  may  be  considered  to be
affiliated  with  the  Company.

On  December  10,  2002,  the registrant had 657,778,000 shares of Common Stock,
$0.001  par  value  per  share,  issued  and  outstanding.

Documents  incorporated  by  reference:  None.

TRANSITIONAL  SMALL  BUSINESS  DISCLOSURE  FORMAT:  Yes [ ]  No [X]


<PAGE>
<TABLE>
<CAPTION>
                                      DURO ENZYME PRODUCTS INC.

                                               INDEX TO
                                     ANNUAL REPORT ON FORM 10-KSB
                                FOR THE YEAR ENDED SEPTEMBER 30, 2002

<S>                                                                                              <C>
PART I                                                                                           PAGE
Item 1     Description of Business. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     3
Item 2     Description of Property. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     5
Item 3     Legal Proceedings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     5
Item 4     Submission of Matters to a Vote of Security Holders. . . . . . . . . . . . . . . . .     6

PART II
Item 5     Market for Common Equity and Related Stockholder Matters . . . . . . . . . . . . . .     7
Item 6     Management's Discussion and Analysis of Financial Condition or Plan of Operations. .     7
Item 7     Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    13
Item 8     Changes In and Disagreements With Accountants on Accounting and Financial Disclosure    13

PART III
Item 9     Directors, Executive Officers, Promoters and Control Persons; Compliance With
           Section 16(a) of the Exchange Act. . . . . . . . . . . . . . . . . . . . . . . . . .    14
Item 10    Executive Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    16
Item 11    Security Ownership of Certain Beneficial Owners and Management . . . . . . . . . . .    17
Item 12    Certain Relationships and Related Transactions . . . . . . . . . . . . . . . . . . .    17
Item 13    Exhibits and Reports on Form 8-K . . . . . . . . . . . . . . . . . . . . . . . . . .    19

SIGNATURES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    20

FINANCIAL STATEMENTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .    21
</TABLE>


                                        2
<PAGE>
                                     PART I

                           FORWARD-LOOKING STATEMENTS
                           --------------------------

Except  for  the  historical information presented in this document, the matters
discussed  in  this  Form  10-KSB,  and  specifically  in the sections entitled,
"Description of Business" and "Management's Discussion and Analysis of Financial
Condition  or  Plan  of  Operation," or otherwise incorporated by reference into
this  document  contain "forward-looking statements" (as such term is defined in
the  Private  Securities Litigation Reform Act of 1995). These statements can be
identified  by  the  use  of  forward-looking  terminology  such  as "believes",
"expects",  "may",  "will",  "intends",  "should",  or  "anticipates"  or  the
negative  thereof  or  other variations thereon or comparable terminology, or by
discussions  of  strategy  that involve risks and uncertainties. The safe harbor
provisions  of  Section  21B of the Securities Exchange Act of 1934, as amended,
and  Section  27A  of  the  Securities  Act  of  1933,  as  amended,  apply  to
forward-looking  statements  made  by the Registrant. You should not place undue
reliance on forward-looking statements. Forward-looking statements involve risks
and  uncertainties,  including  those  identified  within  the  section entitled
"Outlook:  Issues  and  Uncertainties"  and  elsewhere  in,  or  incorporated by
reference  into,  this  Form  10-KSB.  The  actual  results  that the Registrant
achieves  may  differ materially from any forward-looking statements due to such
risks  and  uncertainties. These forward-looking statements are based on current
expectations,  and  the  Registrant  assumes  no  obligation  to  update  this
information.  Readers  are  urged  to  carefully review and consider the various
disclosures  made  by the Registrant in this Annual Report on Form 10-KSB and in
the Registrant's other reports filed with the Securities and Exchange Commission
that  attempt  to  advise  interested  parties of the risks and factors that may
affect  the  Registrant's  business.

ITEM  1.  DESCRIPTION  OF  BUSINESS
-----------------------------------

CORPORATE BACKGROUND

Duro  Enzyme  Products  Inc.  (formerly  -  Home.Web, Inc.) (the "Company") is a
Nevada  corporation  incorporated  on September 15, 1995. From 1997 to 2000, the
Company's  business  plan  consisted  of organizing a gourmet food and specialty
cheese  business  over  the  Internet.

On October 16, 2000, the Company conducted a voluntary share exchange whereby it
offered  up to 28,800,000 shares of its common stock to the shareholders of Duro
Enzymes  Products Inc., a private Nevada corporation formed on November 29, 1999
("Duro  Enzymes  Private"),  in  exchange  for all of the issued and outstanding
shares  of  Duro  Enzymes  Private.  The  effect  of  the share exchange was the
transfer  of control of the Company to the shareholders of Duro Enzymes Private.
Consequently,  the  majority  of  shares  of  the Company are now held by former
shareholders  of  Duro  Enzymes  Private.  At  this  point, Duro Enzymes Private
merged  with and into the Company and changed the focus of its business from the
distribution  and sale of gourmet foods and specialty cheeses over the Internet,
to  the  business  of  Duro  Enzymes  Private,  involving the use of proprietary
technologies  to  produce  natural  and  stable  enzymes,  and  the research and
development  of  various  applications  for  them.  Following  approval  by  the
Company's  shareholders  at  a special shareholders' meeting held on February 5,
2001,  the  Company's  name was formally changed to Duro Enzyme Products Inc. In
connection  with  the  change  in business, new directors and executive officers
were appointed.  On March 8, 2002 the Company instituted a 20 to 1 forward stock
split.

The  Company's principal executive offices are at 20436 Fraser Highway, Langley,
British  Columbia,  V3A  4G2,  Canada.

PLANNED  FUTURE  OPERATIONS
---------------------------

The  Company's  Board  of  Directors  has  decided to change the business of the
Company and effective as of September 27, 2002 decided to review the acquisition
of  its  wholly  owned  subsidiary  Bruden  Steaming and Vac Truck Services Ltd.
("Bruden").  Subsequent  to  the  Balance  Sheet  date  the  board of Director's
reviewing  the  financial statements and financial performance of Bruden decided
to  dispose  of  Bruden.

The  Company  is  currently  reviewing  its  licensed technology agreements with
529473  B.C.  Ltd.  but  has  not  made  any  decisions as to the future on this
particular  business.


                                        3
<PAGE>
The  Company  has  no  plans to pursue the definitive agreement with APC Export,
Inc.  at  this  time.

The  Company  has  been  negotiating  with  new business partners on several new
business  lines  but  no  formal  agreements  have  been  reached.

TECHNOLOGY  LICENSE
-------------------

On  September 21, 2000, 529473 B.C. Ltd., a private British Columbia corporation
(the  licensor)  and  Duro  Solutions,  a  Nevada  corporation  and wholly-owned
subsidiary  of  the  Company,  entered into a License and Distribution Agreement
(the  "License  Agreement"),  which granted to Duro Solutions (the licensee) the
exclusive  right  to use 529473 B.C. Ltd.'s proprietary stable enzyme production
technologies  anywhere  in  the  world.  Through  the  application  of  these
technologies,  Duro  Solutions  has  the  ability to manufacture unique, stable,
natural  enzymes that have a wide range of applications in biological processes.
Under  the  terms  of the License Agreement, Duro Solutions is to pursue further
research  and  development  of  the  proprietary  technologies,  and  market and
distribute  the  resulting  stable enzymes. The License Agreement also grants to
Duro  Solutions  the  right  to sublicense the use of the enzyme technologies in
connection  with  owning  and  operating  a  stable  enzyme  manufacturing  and
production  facility.

Under  the  terms  of the License Agreement, the Company has made a US$2,500,000
promissory  note  bearing interest at a rate of 5% per annum over a period of 10
years  payable  to  529473  B.C.  Ltd.  The  obligation  to make payments on the
promissory  note  does  not  commence  until  the  Company begins selling stable
enzymes.  At  that  time,  the  Company is obligated to pay the entire principal
amount  and  any  accrued  interest within five years. Interest will continue to
accrue  throughout  the  term  of  the  note. In addition, the Company must make
royalty  payments  equal  to 2.5% of gross revenue generated by the Company from
use  of  the  licensed  technologies.  The  royalty payments are to be made on a
quarterly basis. Any further developments of the technologies by the Company are
to  be owned by Duro Solutions. Duro Solutions must assist 529473 B.C. Ltd. with
protection  of  its  intellectual  property  through  patent  applications  and
trademark  registrations.

The  License  Agreement  terminates  if either party fails to perform a material
obligation  under  the Agreement for a period of 30 days after receipt of notice
by  the  defaulting  party  from  the  other  party.  In such a case, all legal,
beneficial  and proprietary rights, title and interest in and to the technology,
plans,  know  how,  any research and development work, including all information
and documentation relating thereto, will remain the sole property of 529473 B.C.
Ltd.  Duro  Solutions  will  own any other basic knowledge or technology used in
any research or development.  Duro Solutions will be obligated to provide 529473
B.C.  Ltd.  with  complete  information  concerning  all  sublicense  agreements
executed  prior  to  termination.  Any  dispute  between  the  parties  is to be
referred  to  an  arbitrator  for  resolution.

The Company is party to Research and Development Services Agreements with 529473
B.C.  Ltd.  Under  the terms of the Agreements, the Company and its subsidiaries
have  agreed  to  retain  the  services of 529473 B.C. Ltd. to provide research,
development,  design, and related consultations. 529473 B.C. Ltd. will receive a
consulting  fee  at  a  standard  rate, established by the consultants, and will
charge  an  additional  15% on incurred costs as an administrative, overhead and
handling  charge.  The initial term of the Agreements, dated September 21, 2000,
is  five  consecutive  years.  All  successive  renewals  will  be  effective
automatically  with  the  lapse  of  the  current  term.

RESEARCH  AND  DEVELOPMENT
--------------------------

No  stable  enzyme  and energy manufacturing and production facilities have been
constructed  as  of the date of this annual report.  During the year the Company
was  still  developing  the  technology.  The  Company  has  no current plans to
continue  research  into  the  technology.

MARKETING  AND  SALES
---------------------

Until  the  Company  has an operating facility in place, its marketing and sales
activities  will  be  limited.


                                        4
<PAGE>
COMPETITION
-----------

As  the  Company  is  not  currently  pursuing  its  stable  enzyme-producing
technologies  and  processes,  no  competition  exists.

INTELLECTUAL  PROPERTY  PROTECTION
----------------------------------

The  License  Agreement  between  the  Company and 529473 B.C. Ltd. provides the
Company  with  the  right  to  use  the stable enzyme-producing technologies and
processes,  and  all  trademarks,  trade  names  and  proprietary  information
associated  with  the  technology  and production processes owned by 529473 B.C.
Ltd.

529473  B.C.  Ltd.,  is  in  the  process  of  filing for US and Canadian patent
protection  for  certain  of  its  processes.  Confidentiality  policies  are
internally implemented by the Company to protect the proprietary information and
know-how.

EMPLOYEES
---------

As  of  December  10,  2002,  the  Company  had  seven  consultants.  Of  those
consultants,  3  were  classified  as  executive officers, two as administrative
personnel, and two sales and marketing.  The Company's consultants do not belong
to a collective bargaining unit, and the Company is not aware of any labor union
organizing  activity.  The  Company  believes  its future success will depend in
large  part  on  its  continuing  ability  to  attract, train and retain skilled
technical,  sales,  marketing  and  customer  support  personnel.

ITEM  2.  DESCRIPTION  OF  PROPERTY
-----------------------------------

The  Company's  principal executive offices are located at 20436 Fraser Highway,
Langley,  British  Columbia,  V3A  4G2,  CANADA.  There  it leases approximately
12,000  square  feet  at a monthly rate of US$14,624 from Brampton Holdings Ltd.
The  Company  is continuing on a month to month basis.  The Company is currently
negotiating  with  the  new  landlord  for  a  new  lease.

ITEM  3.  LEGAL  PROCEEDINGS
----------------------------

The  Company was named in a legal suit filed on November 20, 2001.  The suit has
been  filed  against  it,  its  officers  and  directors,  and others, by Thermo
Tech(TM)  Technologies Inc. and subsidiaries (collectively "Thermo Tech"). There
are  a total of 75 defendants named in the suit. The Company intends to deny the
substance of Thermo Tech's allegations. The Company has filed an appearance with
the  Supreme  Court  of  British  Columbia and will develop its formal technical
legal  response  in  conjunction  with  its  legal  counsel.

Thermo  Tech  alleges  that  the  Company  and  its  officers and directors have
appropriated,  or  in  the  alternative  attempted  to  appropriate,  corporate
opportunities  from  the Plaintiffs through the unauthorized use of confidential
information  and  trade  secrets  owned  by  the  Plaintiffs. As a result of the
alleged  unlawful  actions  of  the  Company  and  its  officers  and directors,
Plaintiffs claim that they have suffered loss, damage and expense. In the prayer
for  relief,  Plaintiffs  seek  the  following  relief  from  the  court:

     -    An  injunction against the Company from unlawfully marketing and using
          the  Thermo  Tech  Process  (defined  in  the  Statement of Claim as a
          process  that  incorporates  the  use  of  thermophilic,  aerobic
          microorganisms  which produce enzymes in a multiple stage fermentation
          process  to  create  high  protein  animal  feed  from organic waste);
     -    Damages  for  unlawfully  marketing and using the Thermo Tech Process;
     -    Damages  for  interference with the Plaintiffs' contractual relations;
     -    Damages  for appropriation of the Plaintiffs' corporate opportunities;
     -    Punitive  damages;
     -    Exemplary  damages;  and
     -    Special  costs,  or  in  the  alternative,  increased  costs.


                                        5
<PAGE>
The  Company believes that Thermo Tech's allegations against it have no basis in
fact,  and  are  without  merit.  As  Thermo Tech states in its press release of
November  20,  2001,  announcing  the  lawsuit:  "[T]he  lawsuit  contains  only
allegations,  not  proven  facts,  and each of these allegations will have to be
proven  by [Thermo Tech] at a trial between the parties." The Company intends to
vigorously  defend this lawsuit and to assert all appropriate counterclaims. Due
to  the  complexities of the lawsuit and the contractual and other relationships
between  the parties to the lawsuit, the Company cannot predict what the outcome
of  the  lawsuit  may  be or reasonably estimate the financial effect associated
with  it.

The  Company  was  named  in  a  lawsuit  on April 23, 2002.  The suit was filed
against  it and its subsidiary Duro Enzyme Solutions Inc by a former officer and
director of the company. The lawsuit is for alleged unpaid monies, in the amount
of  $28,555.  The  company  feels that this allegation is without merit and will
defend  this  action  accordingly.

Except  as  described  above,  to  the  knowledge  of  the  Company's  executive
management  and directors, neither the Company nor its subsidiaries are party to
any other legal proceeding or litigation and none of its property is the subject
of  a  pending legal proceeding and the executive officers and directors know of
no  other  threatened  or  contemplated  legal  proceedings  or  litigation.


ITEM  4.  SUBMISSION  OF  MATTERS  TO  A  VOTE  OF  SECURITY  HOLDERS
---------------------------------------------------------------------

No  matters  were  submitted to the shareholders during the year ended September
30,  2002.


                                        6
<PAGE>
                                     PART II

ITEM  5.  MARKET  FOR  COMMON  EQUITY  AND  RELATED  STOCKHOLDER  MATTERS
-------------------------------------------------------------------------

The  Company's  common  stock  is  traded on the Over-the-Counter Bulletin Board
(OTC-BB)  under  the  symbol  "DEPI."  The  following  table sets forth, for the
periods  indicated,  the  range  of  high  and low sales prices of the Company's
common  stock  as  quoted  by various market makers for the period of October 1,
2001  through  September  30,  2002.

     October 1, 2001 to September 30, 2002:          High*           Low*
                                                    -------         -------
          October to December                       $0.23           $0.1125
          January to March                          $0.2125         $0.065
          April to June                             $0.03           $0.02
          July to September                         $0.01           $0.0075

          *  The  pricing  information  was provided by Edgar Filing System. All
          prices  are  adjusted  for the 20 to 1 forward split which occurred on
          March  8,  2002.


On  December 10, 2002, the Company's issued and outstanding common stock totaled
657,778,000 shares, held by approximately 1,000 shareholders of record and by an
undetermined  number  of  additional shareholders through nominee or street name
accounts  with  brokers.

The  Company  has  not  paid  dividends  in  prior years and has no plans to pay
dividends  in the near future.  The Company intends to reinvest its earnings, if
any  are  achieved,  in the continued development and operation of its business.
Any  payment  of  dividends  would  depend upon the Company's pattern of growth,
profitability,  financial  condition,  and  such  other  factors as the Board of
Directors  may  deem  relevant.

RECENT SALES OF UNREGISTERED SECURITIES

In  October  2000,  the  Company  issued  28,800,000  shares  of common stock in
connection with a voluntary share exchange with the shareholders of Duro Enzymes
Private.  The  issuance  was  exempt  from registration pursuant to Regulation S
under  the  Securities  Act of 1933, as amended, due to the foreign residence of
the  subscribers.  Each  of  the  subscribers  was  provided  with  an  offering
memorandum  prior  to  agreeing  to  the  share  exchange.


ITEM  6.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR PLAN OF
--------------------------------------------------------------------------------
OPERATIONS
----------

The  following  discussion  should  be read in conjunction with the consolidated
financial  statements  included  herein. Certain statements contained herein may
constitute  forward-looking  statements, as discussed at the beginning of Part I
of  this annual report. Because such statements include risks and uncertainties,
actual  results  may  differ  materially from those expressed or implied by such
forward-looking  statements.  Factors  that  could  cause  or contribute to such
differences  include  those discussed in the "Outlook: Issues and Uncertainties"
section  of  this  Form  10-KSB.

During  the  year  the  Company  was  in the business to license and manufacture
unique,  stable,  100%  natural  enzymes.  As  at September 27, 2002 the Company
disposed  of  Bruden,  a  segment  of  its  business.

OVERVIEW

The  Company is a Nevada corporation, incorporated on September 15, 1995.  Since
inception  and  up  through  September 2000, the Company was a development stage
company  focused  on  gourmet  cheese  production  and  distribution.


                                        7
<PAGE>
On  October  16, 2000, the Company acquired Duro Enzymes Products Inc, a private
Nevada  corporation  formed in November 1999, through a voluntary share exchange
with all of the shareholders of Duro Enzymes Private. The former shareholders of
Duro  Enzymes Private now hold 576,000,000 shares of the Company's common stock.
The  Company  effectively  took  control  of  all  of the assets of Duro Enzymes
Private, including its subsidiaries, as a result of the voluntary share exchange
and  subsequent  merger  of Duro Enzymes Private into the Company. Following the
merger,  the Company changed the focus of its business from the sales of gourmet
and  specialty cheeses over the Internet to its new business of gasification and
stable,  natural  enzyme  production. In connection with the change in business,
new  directors  and  executive  officers were appointed. The Company has carried
forward  an  accumulated  deficit  incurred  during  its  development  stage  of
$1,349,077  from  the  business  of  gourmet  food  and  specialty  cheese.

PLAN  OF  OPERATIONS

Following  the  acquisition  of  Duro  Enzymes  Private on October 16, 2000, the
Business of the Company focused on researching the production of stable enzymes.
The  Company's  business  is  still  in its development stage. Through a license
agreement  executed  between 529473 B.C. Ltd. and Duro Solutions, a wholly-owned
subsidiary  of  the  Company, on September 21, 2000, the Company was granted the
right  to  continue  research and commercial development and use of the licensed
technology  anywhere  in  the  world.  The  Company  spent the fiscal year ended
September  30,  2002  to  further  developing  its  business  plans,  but now is
currently  assessing  other  operational  options.

Under  the  terms  of the License Agreement, the Company has made a US$2,500,000
promissory  note  bearing interest at a rate of 5% per annum over a period of 10
years  payable  to  529473  B.C.  Ltd.  The  obligation  to make payments on the
promissory  note  does  not  commence  until  the  Company begins selling stable
enzymes.  At  that  time,  the  Company is obligated to pay the entire principal
amount  and  any  accrued interest within five years.  Interest will continue to
accrue  throughout  the  term  of  the note.  In addition, the Company must make
royalty  payments  equal  to 2.5% of gross revenue generated by the Company from
use  of  the  licensed  technologies.  The  royalty payments are to be made on a
quarterly  basis.

The  Company  has  not  generated  any  revenue  to  date.

The  Company  changed  its  fiscal  year end from December 31 to September 30 by
unanimous  consent  of  the  Board  of  Directors  on  December  15,  2000.

The  Company's  Board  of  Directors  has  decided to change the business of the
Company  and effective as of September 27, 2002 decided to dispose of its wholly
owned  subsidiary  Bruden.  The  Company  is  currently  reviewing  its licensed
technology agreements with 529473 B.C. Ltd. but has not made any decisions as to
its  future  plans  regarding  this  business.

The  Company  has  been  negotiating  with  new business partners on several new
business  lines  but  no  formal  agreements  have  been  reached.

LIQUIDITY  AND  CAPITAL  RESOURCES

No material commitments for capital expenditures were made during the year ended
September 30, 2002.  During the nine months ended September 30, 2000 Duro Enzyme
Private  arranged  for  a  US$2.5  Million long-term Note Payable to acquire the
License  of  the  enzyme  technology.

Repayment  of  the  US$2.5  Million  note will begin six months after commercial
revenue  is earned by the Company, with full repayment of the note required over
the  following  five  years.

As  of  September  30,  2002,  the  Company  had  a net stockholders' deficit of
$2,713,122,  with  accumulated losses during the development stage of $7,168,616
including  a  loss  of  $5,161,851 during the current year.  The current working
capital  deficit  is  $1,947,607  compared  with  a  working  capital deficit of
$257,957  the previous year.  There can be no assurance that the Company will be
able  to  continue as a going concern or achieve material revenues or profitable
operations.


                                        8
<PAGE>
The  Company  plans  to utilize a combination of internally generated funds from
operations  over  the next year, potential debt and/or equity financings to fund
its short-term and long-term growth.  The availability of future financings will
depend  on  market  conditions.  A  portion of the funds may be used to grow the
business  through  acquisitions  of  other  businesses.

The  forecast  of  the  period  of  time  through  which the Company's financial
resources  will be adequate to support operations is a forward-looking statement
that  involves  risks  and  uncertainties.  The  actual funding requirements may
differ  materially  from this as a result of a number of factors including plans
to  rapidly  expand its new operations. There can be no guarantee that financing
adequate  to  carry  out  the Company's business plan will be available on terms
acceptable  to  the  Company,  or  at  all.

EFFECT  OF  FLUCTUATIONS  IN  FOREIGN  EXCHANGE  RATES

The Company's reporting and functional currency is the US dollar. Currently, all
of  the  Company's  operations  are  located in Canada. Transactions in Canadian
dollars  have  been  translated into U.S. dollars using the current rate method,
such  that  assets  and  liabilities  are translated at the rates of exchange in
effect  at the balance sheet date and revenue and expenses are translated at the
average rates of exchange during the appropriate fiscal period. As a result, the
carrying  value of the Company's investments in Canada is subject to the risk of
foreign  currency  fluctuations.  Additionally,  any  revenues received from the
Company's international operations in other than U.S. dollars will be subject to
foreign  exchange  risk.

RECENT  ACCOUNTING  PRONOUNCEMENTS

In  June  1998,  the  Financial  Accounting  Standards Board issued Statement of
Financial  Accounting  Standards No. 133, "Accounting for Derivative Instruments
and  Hedging  Activities"  (SFAS  No.  133).  SFAS No. 133 requires companies to
recognize  all  derivatives  contracts  as  either  assets or liabilities in the
balance sheet and to measure them at fair value.  If certain conditions are met,
a  derivative  may be specifically designated as a hedge, the objective of which
is  to  match  the  timing of gain or loss recognition on the hedging derivative
with the recognition of (i) the changes in the fair value of the hedged asset or
liability  that  are attributable to the hedged risk or (ii) the earnings effect
of  the  hedged  forecasted  transaction.  For  a derivative not designated as a
hedging  instrument,  the  gain or loss is recognized in income in the period of
change.  SFAS  No.  133  is  effective  for  all fiscal quarters of fiscal years
beginning  after  June  15,  2000.

Historically,  the  Company has not entered into derivatives contracts either to
hedge existing risks or for speculative purposes.  Accordingly, the Company does
not  expect  adoption  of  the  new  standard  on  January 1, 2001 to affect its
financial  statements.

In  December  1999,  the  SEC  staff released Staff Accounting Bulletin No. 101,
"Revenue  Recognition  in  Financial  Statements" ("SAB 101").  SAB 101 provides
interpretive guidance on the recognition, presentation and disclosure of revenue
in  the  financial  statements.  SAB  101  must  be  applied  to  the  financial
statements  no  later  than  the quarter ending September 30, 2000.  The Company
does not believe that the adoption of SAB 101 will have a material affect on the
Company's  financial  results.

In  March  2000,  the Financial Accounting Standards Board issued Interpretation
No.  44  ("FIN  44")  Accounting  for  Certain  Transactions  Involving  Stock
Compensation,  an  Interpretation  of  APB Opinion No. 25.  FIN 44 clarifies the
application  of  APB  No.  25 for (a) the definition of employee for purposes of
applying  APB  No. 25, (b) the criteria for determining whether a plan qualifies
as  a  non-compensatory  plan,  (c)  the  accounting  consequences  of  various
modifications  to the terms of a previously fixed stock option or award, and (d)
the  accounting  for  an  exchange  of  stock  compensation awards in a business
combination.  FIN  44  is  effective July 2, 2000, but certain conclusions cover
specific  events that occur after either December 15, 1998, or January 12, 2000.
The  Company  will  adopt  FIN  44  in accounting for the stock options granted.

In  March  2000,  EITF  00-2  "Accounting  for  Web  Site Development Costs" was
released.  EITF 00-2 provides guidance on how an entity should account for costs
involved in such areas as planning, developing software to operate the web site,
graphics,  content, and operating expenses.  EITF 00-2 is effective for web site
development  costs  incurred  for fiscal quarters beginning after June 30, 2000.


                                        9
<PAGE>
OUTLOOK:  ISSUES  AND  UNCERTAINTIES

Shareholders  and  prospective  purchasers  of the Company's Common Stock should
carefully  consider  the  following  risk  factors  in  addition  to  the  other
information  appearing  in  this  Annual  Report  on  Form  10-KSB.

BUSINESS  RISKS
---------------

     THE  COMPANY  MAY  ACQUIRE  UNRELATED  BUSINESS  AND  CHANGE  ITS  CURRENT
     OPERATIONS.

The  Company  is  currently  looking  at  other  business  models  and  business
operations.  These  new  operations may be materially different from the current
business  model  and operation that currently exist.  Any change in the business
operations  may  materially  affect  the  Company's  share  price  and  revenue
generation  ability.

     THE  IMPLEMENTATION OF THE COMPANY'S CURRENT BUSINESS PLAN DEPENDS UPON ITS
     CONTINUED  RELATIONSHIP  WITH  529473  B.C.  LTD.

The  Company's business depends upon technologies and know-how that are owned by
529473  B.C.  Ltd.  and upon the provision of technical expertise by 529473 B.C.
Ltd.  to  the  Company. The Company has entered into Agreements with 529473 B.C.
Ltd.  both  for  use of its technologies to make some of the commercial products
that it intends to produce and sell and for consulting services used to continue
the  research  and  development  of  the  proprietary  gasification  and  stable
enzyme-producing  technologies.  If  the  Company has a disagreement with 529473
B.C.  Ltd.  that  results  in  the severing of its relationship with 529473 B.C.
Ltd.,  the  Company  will  be  unable to implement its business plan or continue
operations  as  planned,  which  would  have  a  severe impact on its ability to
generate  revenue  in  the  future.

     THE  COMPANY  MAY  REQUIRE  ADDITIONAL  EQUITY  FINANCING, WHICH MAY NOT BE
     AVAILABLE  AND  MAY  DILUTE  THE  OWNERSHIP  INTERESTS  OF  INVESTORS.

The  Company's  ultimate  success will depend on its ability to raise additional
capital.  No  commitments  to  provide  additional  funds  have  been  made  by
management  or  other  shareholders.  The  Company  has  not  investigated  the
availability,  source  or  terms that might govern the acquisition of additional
financing.  When  additional capital is needed, there is no assurance that funds
will be available from any source or, if available, that they can be obtained on
terms acceptable to the Company.  If unavailable, the Company's operations could
be  severely limited, and it may not be able to implement its business plan.  If
equity  financing  is  used  to  raise additional working capital, the ownership
interests  of  existing  shareholders  may  be  diluted.

     THE COMPANY'S OPERATING RESULTS ARE LIKELY TO FLUCTUATE SIGNIFICANTLY WHICH
     COULD  INCREASE  THE  VOLATILITY  OF  ITS  STOCK  PRICE.

As  a  result  of  the Company's limited operating history and the planned rapid
expansion  of  its  business  operations,  the  Company's  quarterly  and annual
revenues  and  operating  results are likely to fluctuate from period to period.
For  this  reason,  you  should  not rely on period-to-period comparisons of the
Company's  financial  results  as  indications of future results.  The Company's
future  operating  results  could  fall  below the expectations of public market
analysts  or  investors  and significantly reduce the market price of its common
stock.  Fluctuations  in  the  Company's  operating  results  could increase the
volatility  of  its  stock  price.

     THE  COMPANY'S  DEPENDENCE ON RELATIONSHIPS WITH BUSINESSES AND GOVERNMENTS
     OUTSIDE  OF  THE UNITED STATES MAY NEGATIVELY AFFECT ITS ABILITY TO OPERATE
     ITS  BUSINESS  AS  PLANNED.

The  Company  depends  on  its  ability  to  establish  and  maintain successful
relationships  with  businesses  and  governments  located outside of the United
States.  If  the Company is unable to establish and maintain such relationships,
it will not be able to implement the business plan in its current configuration,
which  will  affect  both its revenue stream and profit potential.  In addition,
the  Company  faces  political  sovereign  risks  of  conducting  international


                                       10
<PAGE>
business,  including  risks  of  changing  economic conditions, which may have a
material  adverse  effect  on  its  ability  to  expand its operations globally.

     THE  COMPANY  MAY  BE  UNABLE  TO  PROTECT ITS INTELLECTUAL PROPERTY, TRADE
     SECRETS  AND  KNOW-HOW  WHICH WOULD REMOVE A BARRIER TO COMPETITION AND MAY
     DIRECTLY  AFFECT  THE  AMOUNT  OF  REVENUE  IT  GENERATES.

The  Company depends heavily on licensed technology to produce unique stable and
natural  enzymes.  The Company is dependent on its ability to keep trade secrets
and  obtain patents on its technologies as well as on its ability to develop new
processes,  technologies  and  products  to  meet  the needs of its marketplace.
Although  the  Company  intends to employ various methods, including trademarks,
patents,  copyrights  and confidentiality agreements with employees, consultants
and  third  party  businesses,  to  protect  its intellectual property and trade
secrets,  there  can  be  no  assurance  that  it  will  be able to maintain the
confidentiality  of  any  of  its  proprietary  technologies,  know-how or trade
secrets,  or that others will not independently develop substantially equivalent
technology.  The  failure  or  inability  to  protect  these rights could have a
material  adverse  effect  on  the  Company's  operations.

     THE  COMPANY  DEPENDS  UPON  A SMALL NUMBER OF KEY PERSONS TO IMPLEMENT ITS
     BUSINESS  PLAN,  AND  THE  LOSS  OF  ANY  OF  THEM  MAY AFFECT ITS BUSINESS
     OPERATIONS.

The  Company  is  dependent on several key consultants to implement its business
plan,  and  the  loss of any of them may affect the Company's ability to provide
the  required  quality of service and technical support necessary to achieve and
maintain  a  competitive  market  position. There is no assurance that these key
employees  and  consultants will continue to manage the Company's affairs in the
future.  The  Company  has not obtained key man insurance with respect to any of
its  consultants.

     THE  COMPANY  MAY  NOT BE ABLE TO EFFECTIVELY MANAGE ITS GROWTH WHICH COULD
     HAVE  A  MATERIAL  EFFECT  ON  ITS  BUSINESS  OPERATIONS.

The  Company's  ability to manage its growth depends in part upon its ability to
develop and expand operating, management, information and financial systems, and
production  capacity,  which  may  significantly  increase  its future operating
expenses.  No  assurance can be given that it will grow in the future or that it
will  be  able  to  effectively manage such growth.  Its inability to manage its
growth  successfully  could  have  a  material  adverse  effect on its business,
financial  condition and results of operations.  The Company cannot successfully
implement its business model if it fails to manage its growth. The Company plans
to  rapidly  and  significantly  expanded  its  operations  domestically  and
internationally  and  anticipates  further expansion to take advantage of market
opportunities.

INVESTMENT  RISK
----------------

     CONCENTRATION OF OWNERSHIP OF DIRECTORS, OFFICERS AND SIGNIFICANT EMPLOYEES
     MAY  REDUCE  THE  CONTROL  BY  OTHER  SHAREHOLDERS  OVER  THE  COMPANY.

The Company's directors, officers and other control persons own or exercise full
or  partial  control  over  more  than 14.3% of the Company's outstanding common
stock.  As  a result, other investors in the Company's common stock may not have
much  influence  on corporate decision-making. In addition, the concentration of
control  over  the  Company's  common  stock  among the insiders could prevent a
change  in  control  of  the  Company.

     THE  COMPANY'S  COMMON  STOCK IS CONSIDERED A "PENNY STOCK", WHICH MAKES IT
     MORE  DIFFICULT  TO  SELL  THAN  AN  EXCHANGE-TRADED  STOCK.

The  Company's  securities are subject to the Securities and Exchange Commission
rule  that  imposes special sales practice requirements upon broker-dealers that
sell  such  securities  to  other  than  established  customers  or  accredited
investors.  For purposes of the rule, the phrase "accredited investor" means, in


                                       11
<PAGE>
general  terms,  institutions  with  assets  exceeding $5,000,000 or individuals
having net worth in excess of $1,000,000 or having an annual income that exceeds
$200,000  (or  that,  combined  with  a  spouse's income, exceeds $300,000). For
transactions  covered  by  the  rule,  the  broker-dealer  must  make  a special
suitability  determination for the purchaser and receive the purchaser's written
agreement  to  the  transaction  prior  to  the sale. Consequently, the rule may
affect  the  ability of purchasers of the Company's securities to buy or sell in
any  market  that  may  develop.

In  addition,  the  Securities  and  Exchange Commission has adopted a number of
rules  to  regulate "penny stocks." (A "penny stock" is any equity security that
has  a  market  price  of less than $5.00 per share or with an exercise price of
less  than  $5.00  per share, subject to certain exceptions). Such rules include
Rules  3a51-1,  15g-1,  15g-2,  15g-3,  15g-4, 15g-5, 15g-6, and 15g-7 under the
Securities  and  Exchange  Act of 1934, as amended. The rules may further affect
the  ability  of  owners of the Company's shares to sell their securities in any
market  that  may develop for them. Shareholders should be aware that, according
to  the  Securities and Exchange Commission Release No. 34-29093, the market for
penny stocks has suffered in recent years from patterns of fraud and abuse. Such
patterns  include:

     -    control  of the market for the security by one or a few broker-dealers
          that  are  often  related  to  the  promoter  or  issuer;
     -    manipulation  of  prices through prearranged matching of purchases and
          sales  and  false  and  misleading  press  releases;
     -    "boiler  room"  practices  involving  high  pressure sales tactics and
          unrealistic  price  projections  by  inexperienced  sales  persons;
     -    excessive and undisclosed bid-ask differentials and markups by selling
          broker-dealers;  and
     -    the  wholesale  dumping  of  the  same  securities  by  promoters  and
          broker-dealers  after prices have been manipulated to a desired level,
          along  with  the  inevitable  collapse of those prices with consequent
          investor  losses.

     THE  ISSUANCE  OF  ADDITIONAL  SHARES  MAY  HAVE THE EFFECT OF DILUTING THE
     INTEREST  OF  SHAREHOLDERS.

Any  additional issuances of common stock by the Company from its authorized but
unissued  shares  may  have  the  effect  of diluting the percentage interest of
existing  shareholders.  Out  of  the  Company's 3,200,000,000 authorized common
shares,  2,542,222,000  or  approximately  79.4% remain unissued at December 10,
2002.  The  Board  of  Directors  has  the  power  to  issue such shares without
shareholder  approval. None of the 40,000,000 authorized preferred shares of the
Company  are issued. The Company fully intends to issue additional common shares
or  preferred  shares  in order to raise capital to fund its business operations
and  growth objectives or as compensation for services rendered on behalf of the
Company.

     BOARD  OF  DIRECTORS'  AUTHORITY TO SET RIGHTS AND PREFERENCES OF PREFERRED
     STOCK  MAY  PREVENT  A  CHANGE  IN CONTROL BY STOCKHOLDERS OF COMMON STOCK.

Preferred  shares  may  be  issued  in  series  from  time  to  time  with  such
designation,  rights,  preferences  and  limitations  as  the Company's Board of
Directors  determines by resolution and without shareholder approval. This is an
anti-takeover  measure. The Board of Directors has exclusive discretion to issue
preferred  stock  with rights that may trump those of common stock. The Board of
Directors  could  use  an  issuance  of  Preferred Stock with dilutive or voting
preferences  to  delay,  defer  or prevent common stockholders from initiating a
change  in control of the Company or reduce the rights of common stockholders to
the  net  assets upon dissolution. Preferred stock issuances may also discourage
takeover  attempts  that  may  offer premiums to holders of the Company's common
stock.

     STOCKHOLDERS  DO  NOT  HAVE THE AUTHORITY TO CALL A SPECIAL MEETING THEREBY
     DISCOURAGING  TAKEOVER  ATTEMPS.

Pursuant to the Company's articles of incorporation, only the Company's Board of
Directors  has  the power to call a special meeting of the stockholders, thereby
limiting  the  ability  of  stockholders  to  effect  a change in control of the
Company.


                                       12
<PAGE>
     THE  COMPANY  DOES NOT ANTICIPATTE PAYING DIVIDENDS TO ITS SECURITY HOLDERS
     IN  THE  FORESEEABLE FUTURE WHICH MAKES INVESTMENT IN ITS STOCK SPECULATIVE
     OR  RISKY.

The  Company  has not paid dividends on its common stock and does not anticipate
paying  dividends  on  its  common stock in the foreseeable future. The Board of
Directors  has  sole  authority  to  declare  dividends payable to the Company's
shareholders.  The  fact  that  the  Company  has  not  and does not plan to pay
dividends  indicates  that  the  Company  must use all of its funds generated by
operations for reinvestment in its operating activities and also emphasizes that
the Company may not continue as a going concern. Investors also must evaluate an
investment  in  the  Company  solely  on the basis of anticipated capital gains.

     LIMITED  LIABILITY  OF  THE  COMPANY'S EXECUTIVE OFFICERS AND DIRECTORS MAY
     DISCOURAGE  STOCKHOLDERS  FROM  BRINGING  A  LAWSUIT  AGAINST  THEM.

The Company's articles of incorporation and bylaws contain provisions that limit
the  liability of directors for monetary damages and provide for indemnification
of  officers  and  directors.  These provisions may discourage stockholders from
bringing a lawsuit against officers and directors for breaches of fiduciary duty
and may also reduce the likelihood of derivative litigation against officers and
directors even though such action, if successful, might otherwise have benefited
the  stockholders. In addition, a stockholder's investment in the Company may be
adversely  affected  to  the  extent  that costs of settlement and damage awards
against  officers  or  directors  are  paid  by  the  Company  pursuant  to  the
indemnification  provisions  of  the  articles of incorporation and by-laws. The
impact on a stockholder's investment in terms of the cost of defending a lawsuit
may  deter  the  stockholder  from  bringing  suit  against one of the Company's
officers  or  directors.  The  Company  has  been advised that the SEC takes the
position that this provision does not affect the liability of any director under
applicable  federal  and  state  securities  laws.


ITEM  7.  FINANCIAL  STATEMENTS
-------------------------------

Financial  statements  and  supplementary  data  are set forth on pages F-1 thru
F-11.

ITEM  8.  CHANGES  IN  AND  DISAGREEMENTS  WITH  ACCOUNTANTS  ON  ACCOUNTING AND
--------------------------------------------------------------------------------
FINANCIAL  DISCLOSURE
---------------------

None.


                                       13
<PAGE>
                                    PART III

ITEM  9.  DIRECTORS,  EXECUTIVE  OFFICERS,  PROMOTERS  AND  CONTROL  PERSONS;
-----------------------------------------------------------------------------
COMPLIANCE  WITH  SECTION  16(A)  OF  THE  EXCHANGE  ACT
--------------------------------------------------------

The  following  individuals were directors and executive officers of the Company
on  September  30,  2001:

<TABLE>
<CAPTION>
<S>                <C>
     Robert L. Jackman  Director, President and Treasurer
     Dean Branconnier   Director and Vice President
     Chad Burback       Director and Secretary

The following individuals were appointed as Director's and executive officers of
the  Company:

     Perry Smith        Director (January 30, 2002)
     David Kirske       CFO (January 30, 2002) - (Resigned March 11, 2002)
     James C. Florio    Director, Chairman (March 19, 2002) - (Resigned August 29, 2002)
     Ralph Petruzzo     Director (May 22, 2002)
     Larry Gold         Director (July 23, 2002) - (Resigned October 22, 2002)
</TABLE>

On March 19, 2002 the Board of Directors of the Company accepted the resignation
of  Robert  L.  Jackman  and  appointed:

     Perry Smith        President

The  following  table sets forth the name, age and position of each Director and
Executive  Officer  of  the  Company  as  of  September  30,  2002.

     NAME              AGE  POSITION
     ----              ---  --------
     Perry Smith        41  President and Director of Duro Enzyme

     Dean Branconnier   33  Vice President and Director of Duro Enzyme

     Chad Burback       26  Secretary and Director of Duro Enzyme

     Ralph Petruzzo     50  Director

     Larry Gold         58  Director


PERRY  SMITH  -  PRESIDENT  AND  DIRECTOR
-----------------------------------------

Mr.  Smith brings an extensive background in the design, building, commissioning
and  operation  of a wide variety of environmental industrial systems. Mr. Smith
has  the  experience and know-how to build and operate the Company's  production
facilities,  as well as provide the leadership and innovation to drive corporate
growth, optimize plant performance, and chart long-term success for the Company.
His  past  accomplishments  include bringing an industrial environmental project
management  company  from  $2-million  to $15-million in sales in less than five
years,  increasing  the  client  base  by  300%,  and  increasing to significant
profitability.

MR.  DEAN  BRANCONNIER  -  VICE  PRESIDENT  AND  DIRECTOR
---------------------------------------------------------

Over  the past year, Mr. Dean Branconnier has assisted with the organization and
development  of  the Company.  Prior to the year 2000, Mr. Branconnier was Plant
Manager  for  Richmond Bio Conversion Inc. in Richmond, British Columbia, Canada
(1998-2000)  and  for  Hamilton Bio Conversion Inc. in Hamilton, Ontario, Canada
(1995-1998).  As  Plant  Manager,  Mr.  Branconnier had the following duties and
responsibilities:  assist  with  project  schedules  and construction contracts;


                                       14
<PAGE>
plant  operations  and  start  up;  maintain a daily log of all plant events and
manage daily operations; oversee all office administration; manage expenditures;
ensure compliance with permits; conduct performance reviews of employees; ensure
plant  safety  and  security;  and  staff  the  plants.

MR.  CHAD  BURBACK  -  SECRETARY  AND  DIRECTOR
-----------------------------------------------

Over  the  past  year,  Mr.  Chad Burback has assisted with the organization and
development  of  the  Company.  Mr.  Burback  was Plant Manager for Hamilton Bio
Conversion Inc. in Hamilton, Ontario, Canada (1998-2001).  From 1995 to 1998 Mr.
Burback  was  the  Plant Manager for Brampton Bio Conversion Inc., a Depackaging
and  Recycling facility in Brampton, Ontario, Canada.  As Plant Manager for each
facility,  Mr.  Burback  was responsible for the expansion of the facilities and
had  the  following  duties and responsibilities:  assist with project schedules
and  construction contracts; operations control and management; maintain a daily
log of all plant events; oversee all office administration; manage expenditures;
ensure compliance with permits; conduct performance reviews of employees; ensure
plant  safety  and  security;  and  staff  the  plants.

MR.  RALPH  PERTUZZO  -  DIRECTOR
---------------------------------

Mr.  Petruzzo  is  a  successful  entrepreneur  and  inventor  with  a  focus on
environmental  businesses  and  technologies that use sludges, and other organic
materials,  to  create  high-demand,  high-value  products.  Mr.  Petruzzo's
proprietary  technologies  are  currently  used  in  paper  sludge  drying  and
gasification  systems  that  have  been  operating profitably in New York State,
24-hours a day, 7-days a week, since 1998. Mr. Petruzzo has guided the growth of
Petruzzo  Products Inc., a family-owned, US corporation, which has expanded from
New England's oldest bark mulch manufacturer into a multi-faceted operation that
includes  transportation,  hauling,  equipment  rental,  and  the  production of
biodegradable  products  from top soil to humus, animal bedding to kitty litter,
and  fertilizers  to  decorative  landscaping mulches. Mr. Petruzzo additionally
owns  and  operates  J.B.H. Associates Inc., a developing partner in a 3,000-ton
per  day  landfill in Southern California. This landfill is already permitted to
receive 400-tons per day of bio-solids, an enormous waste management problem for
the  State  of  California  and  excellent  feedstock for enzyme manufacture and
gasification.  Throughout  his  career,  Ralph  Petruzzo  has  fostered business
relationships  with  a  diverse  group  of  individuals  in  a  wide  variety of
industries  and  organizations  including  20  years  with  International  Paper
Company,  Evergreen  Recycling,  the  chains  of  Chase  Pitkin Home Centers and
Hewitts  Garden  Stores, Waste Management of New York, Franklin Mushroom Company
(the  largest  mushroom  growing  facility in North America), Tully Construction
(primary  contractor  to  World Trade Centers recovery site), Blue Circle Cement
(second  largest  US  cement  company),  Kirtland  Air Force Base of New Mexico,
Precision  Environmental  Services,  New  England  Organics,  Wheelabrator
Technologies  - Bio Gro Division, and numerous municipalities. Mr. Petruzzo also
founded  and  operated  Aspen  Construction,  Inc.,  of  Rockland  County, NY, a
commercial  construction  business  that  completed such notable projects as the
world's  first  and  largest  Ferrari  dealership.

MR.  LARRY  GOLD  -  DIRECTOR
-----------------------------

Larry Gold graduated from the University of British Columbia law school in 1973.
He  was  called  to the Bar in 1974 and has had a  successful career  practicing
law  since  that  time.  During  his  career  as  a lawyer to date, Mr. Gold has
specialized  in  business  law,  securities,  and in varied areas of litigation.
While engaging in the practice of law he has also served as a director of public
and  private  companies as well as a consultant to publicly traded companies. He
will  bring  to  the Company a unique understanding of, and ability to negotiate
the  structure  and  content  of  corporate  agreements  as  well  as  the legal
requirements  of  public  companies.


SECTION  16(A)  BENEFICIAL  OWNERSHIP  REPORTING  COMPLIANCE

Directors,  officers  and  beneficial owners of more than 10% of the outstanding
common  stock  of  the  Company  are required by Section 16(a) of the Securities
Exchange  Act  of 1934 to report to the Securities and Exchange Commission their
transactions  in,  and  beneficial  ownership  of,  the  Company's common stock,
including  any  grants  of  options  to  purchase  common stock.  Mr. Smith, Mr.
Branconnier,  Mr.  Burback,  Mr.  Petruzzo  and Mr. Gold have filed with the SEC
Forms  3  and  4.  These  forms  were  filed  after  their due dates as follows:


                                       15
<PAGE>
----------------------------------------------------------------------------
                                                  NUMBER OF TRANSACTIONS NOT
NAME OF REPORTING PERSON  NUMBER OF LATE REPORTS  REPORTED ON A TIMELY BASIS
----------------------------------------------------------------------------
Perry Smith                        1                         None
----------------------------------------------------------------------------
Dean Branconnier                   2                          1
----------------------------------------------------------------------------
Ralph Petruzzo                     1                         None
----------------------------------------------------------------------------
Larry Gold                         1                         None
----------------------------------------------------------------------------
Chad Burback                       1                         None
----------------------------------------------------------------------------


ITEM  10.  EXECUTIVE  COMPENSATION
----------------------------------

The following table sets forth the compensation that the Company has paid to its
President  for the year ended September 30, 2002.  No executive officer received
more  than US$100,000 in annual compensation during the year ended September 30,
2002.  The  Company  does  not  currently have a long-term compensation plan and
does  not  grant any long-term compensation to its executive officers. The table
does not reflect certain personal benefits, which in the aggregate are less than
ten  percent  of  the  President's  salary and bonus.  No other compensation was
granted  for  the  periods  covered.

<TABLE>
<CAPTION>
                                        SUMMARY COMPENSATION TABLE

                                                               Long Term Compensation
                                                         ----------------------------------
                      Annual  Compensation                       Awards             Payouts
---------------------------------------------------------------------------------------------------------
Name                                           Other     Restricted    Securities
and                                            Annual       Stock      Underlying     LTIP     All Other
Principal            Consulting               Compensa    Award(s)      Options/    Payouts    Compensat
Position      Year    fees ($)    Bonus ($)   tion ($)       ($)        SARs (#)      ($)       ion ($)
---------------------------------------------------------------------------------------------------------
<S>          <C>    <C>          <C>         <C>        <C>           <C>          <C>        <C>
Perry Smith   2002  $ 30,519 (2)  N/A        $      Nil  N/A          $        Nil  N/A       $       Nil
(President
&
Treasurer)
---------------------------------------------------------------------------------------------------------
Robert        2002  $  2,580 (1)  N/A        $      Nil  N/A          $        Nil  N/A       $       Nil
Jackman
(former
President &
Treasurer)
---------------------------------------------------------------------------------------------------------
<FN>
(1)  All amounts were paid to FL Tech Inc., an Ontario corporation, of which Dr.
Jackman  is sole principal, for services rendered by Dr. Jackman to the Company.
(2)  Accrued but unpaid.
</TABLE>

During  the  year  ended  September  30,  2002,  the  Company hired consultants,
attorneys  and  independent  accountants  to assist management.  The consultants
received  $420,716  in  fees,  the  attorneys  received  $39,3828  in  fees, the
independent  accountants  received  $55,774  in fees and the executives received
$92,286  in  fees.

COMPENSATION  OF  DIRECTORS

Directors  are not compensated for their service as directors. All directors are
reimbursed  for  any  reasonable  expenses  incurred in the course of fulfilling
their  duties  as  a  director  of  the  Company.

EMPLOYMENT  CONTRACTS

The  Company  has  consulting  contracts with some of its executive officers and
directors.  The  Company may in the future execute additional written consulting
agreements  with  the  consulting  companies owned by its executive officers and
consultants.


                                       16
<PAGE>
ITEM  11.  SECURITY  OWNERSHIP  OF  CERTAIN  BENEFICIAL  OWNERS  AND  MANAGEMENT
--------------------------------------------------------------------------------

The following table sets forth as of December 10, 2002 certain information known
to the Company regarding the beneficial ownership of the Company's common stock,
and as adjusted to reflect the share ownership for (i) each executive officer or
director  of  the  Company  who  beneficially owns shares; (ii) each shareholder
known to the Company to beneficially own five percent or more of the outstanding
shares  of its common stock; and (iii) all executive officers and directors as a
group.  The  Company  believes  that  the  beneficial owners of the common stock
listed  below,  based  on  information  furnished  by  such  owners,  have  sole
investment  and  voting  power with respect to such shares, subject to community
property  laws  where  applicable.  The  individuals  listed  in  the  table are
accessible  at  the  following  address:  20436 Fraser Highway, Langley, British
Columbia,  CANADA,  V3A  4G2.

<TABLE>
<CAPTION>
                                                                                PERCENTAGE OF
NAME AND POSITION                                          NUMBER OF SHARES  OUTSTANDING SHARES
------------------------------------------------------------------------------------------------
<S>                                                        <C>               <C>
Perry Smith - President and Director                                 Nil                      0%
------------------------------------------------------------------------------------------------
Ralph Petruzzo - Director                                            Nil                      0%
------------------------------------------------------------------------------------------------
Dean Branconnier - Vice President and Director                   32,000,000                 4.9%
------------------------------------------------------------------------------------------------
Chad Burback - Secretary and Director                            32,000,000                 4.9%
------------------------------------------------------------------------------------------------
Jolene and Fred Fuller - Shareholders (husband & wife)           62,500,000                 9.5%
------------------------------------------------------------------------------------------------
Terri and Lyle Veillet - Shareholders (husband & wife)           62,500,000                 9.5%
------------------------------------------------------------------------------------------------
Shane & Josie Branconnier - Shareholders (husband & wife)        62,500,000                 9.5%
------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------
ALL CURRENT DIRECTORS AND
OFFICERS AS A GROUP (4 Persons)                                  64,000,000                 9.7%
---------------------------------------------------------  ----------------  -------------------
</TABLE>

CHANGE  IN  CONTROL

The  Company  is  not  aware  of  any  arrangement  that would upset the control
mechanisms  currently  in  place.  Although it is conceivable that a third party
could  attempt  a  hostile takeover of the Company, the Company has not received
notice  of  any  such  effort.

ITEM  12.  CERTAIN  RELATIONSHIPS  AND  RELATED  TRANSACTIONS
-------------------------------------------------------------

On  September  14,  2000,  the  inventors  and  former  owners  of  the  stable
enzyme-production  technology  licensed  to  Duro Solutions by 529473 B.C. Ltd.,
transferred  ownership of their intellectual property rights to 529473 B.C. Ltd.
for  a  nominal  amount.  529473  B.C.  Ltd.  is  owned by Mr. Ren  Branconnier;
accordingly  he  is  the ultimate beneficiary of all agreements and arrangements
between  the  Company  and  529473  B.C.  Ltd.

On  September  21,  2000,  the  Company,  through its subsidiaries, acquired the
license  to  use  the  intellectual  property.  Under  the  terms of the License
Agreement,  the Company has made a US$2,500,000 promissory note bearing interest
at  a rate of 5% per annum over a period of 10 years payable to 529473 B.C. Ltd.
The  obligation  to make payments on the promissory note does not commence until
the  Company  begins  selling  stable  enzymes.  At  that  time,  the Company is
obligated  to  pay  the  entire principal amount and any accrued interest within
five  years.  Interest  will continue to accrue throughout the term of the note.
In  addition,  the  Company  must  make  royalty payments equal to 2.5% of gross
revenue  generated  by  the  Company  from use of the licensed technologies. The
royalty  payments  are to be made on a quarterly basis. Any further developments
of  the  technologies  by  the  Company  are to be owned by 529473 B.C. Ltd. and
licensed  to  Duro  Solutions.  Duro Solutions must assist 529473 B.C. Ltd. with
protection  of  its  intellectual  property  through  patent  applications  and
trademark  registrations.

Also on September 21, 2000, the Company became party to Research and Development
Services Agreements with 529473 B.C. Ltd. Under the terms of the Agreements, the
Company  and  its subsidiaries have agreed to retain the services of 529473 B.C.
Ltd. to provide research, development, design, and related consultations. 529473
B.C.  Ltd.  will receive a consulting fee at a standard rate, established by the
consultants,  and  will  charge  an  additional  15%  on  incurred  costs  as an
administrative,  overhead  and  handling  charge.  The  initial  term  of  the


                                       17
<PAGE>
Agreements,  dated September 21, 2000, is five consecutive years. All successive
renewals  will  be  effective  automatically with the lapse of the current term.

As  a  result  of the Company acquiring the License and accrued interest, 529473
B.C. Ltd. is owed $2,752,738 under a note payable with annual interest of 5% per
annum.

During  the  fiscal  year  ended  September  30,  2002, the Company entered into
short-term  loans  with  529473  B.C.  Ltd.,  totaling  $447,249  at  year  end.

During  the  fiscal  year  ended  September  30,  2002, the Company entered into
transactions  for  consulting  services  with  11  companies  that  are owned or
controlled  by shareholders or creditors of the Company.  At September 30, 2002,
the  amount  outstanding  and  unpaid  is  $401,955.

The Company also leased office space from Brampton Holdings Ltd., which is owned
by  Sharon  Branconnier  and  Jolene Fuller, wife and daughter, respectively, of
Rene  Branconnier.  The  Company  owes accrued rent for one and onehalf years of
$176,612.

Under  the  SEC's  rules,  Mr.  Ren  Branconnier  and  Dr. Robert Jackman may be
considered  promoters  or  founders  of  Duro Enzymes Private and, following the
October 16, 2000 voluntary share exchange, the Company.  Dr. Robert Jackman owns
1,500,000  shares of the Company and during 2002 provided consulting services to
the  Company  through  FL  Tech  Inc.  for  which  $2,580  was  paid.  Mr.  Ren
Branconnier  owns  750,000  shares  of  the  Company  and  during  2002 provided
consulting  services  to  the  Company  through  529473  B.C.  Ltd. and Sanclair
Holdings  Ltd.  for  which $150,450 was accrued.  Mr. Ren  Branconnier also owns
529473  B.C.  Ltd.; accordingly he is the ultimate beneficiary of all agreements
and  arrangements  between  the  Company  and  529473  B.C. Ltd.  The agreements
between  529473  B.C. Ltd. and the Company and its subsidiaries were approved by
the  Company's  Board of Directors.  FL Tech a company controlled by  Dr. Robert
Jackman performed consulting work for 529473 B.C. Ltd.; Mr. Dean Branconnier and
Mr.  Chad  Burback  are  Mr.  Ren  Branconnier's  nephews.


                                       18
<PAGE>
ITEM  13.  EXHIBITS  AND  REPORTS  ON  FORM  8-K
------------------------------------------------

EXHIBITS

Exhibit
Number     Description
------     -----------
3.1****    Amended  and  Restated Articles of Incorporation dated February 5,
           2001

3.2****    Amended  and  Restated  Bylaws  dated  January  8,  2001

4.1**      Specimen Stock Certificate for Shares of Common Stock of the Company

10.1*****  Lease  Agreement  dated  December  12,  2001

10.2***    License  and  Distribution  Agreement between 529473 B.C. Ltd. and
           Duro Enzyme  Solutions  Inc.  (U.S.), as amended, dated September 21,
           2000

10.3*      Research and Development Services Agreement between 529473 B.C. Ltd.
           and Duro  Enzyme Solutions Inc. (Canada), as amended, dated September
           21,  2000

10.4*      Research and Development Services Agreement between 529473 B.C. Ltd.
           and Duro Enzyme Solutions Inc. (U.S.), as amended, dated September
           21, 2000
16.1*****  Letter  from  BDO  Dunwoody,  Chartered Accountants, to the U.S.
           Securities  and  Exchange  Commission

16.2*****  Letter  from  Raber  Mattuck, Chartered Accountants, to the U.S.
           Securities  and  Exchange  Commission

21.1       List of Subsidiaries

23.0       Consent Letter

*  Filed  on  November  20,  2000, as an exhibit to the Company's report on Form
10-QSB  for the three months ended September 30, 2000 and incorporated herein by
reference
**  Filed  on  December  29,  2000,  as an exhibit to the Company's transitional
report  on  Form  10-KSB  for  the  nine  months  ended  September  30, 2000 and
incorporated  herein  by  reference
***  Filed  on  February 14, 2001, as an exhibit to the Company's report on Form
10-QSB  for  the three months ended December 31, 2000 and incorporated herein by
reference.
**** Filed on May 15, 2001, as an exhibit to the Company's report on Form 10-QSB
for the three months ended March 31, 2001, and incorporated herein by reference.
*****  Filed on December 29, 2001, as an exhibit to the Company's report on Form
10-KSB  for  the  year  ended  September  30,  2001,  and incorporated herein by
reference.

REPORTS  ON  FORM  8-K

No  reports  on  Form 8-K were filed by the Company during the fourth quarter of
the  fiscal  year  ended  September  30,  2002.



                                       19
<PAGE>
SIGNATURES
----------

In  accordance  with  Section  13  or  15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                   DURO ENZYME PRODUCTS INC.

                   By:  /s/  Perry  Smith
                       ---------------------------
                       Perry Smith
                       President and Director

                   Date: December 24, 2002
                       ---------------------------


In  accordance  with  the Exchange Act, this report has been signed below by the
following  persons  on behalf of the registrant and in the capacities and on the
dates  indicated.

                   By:  /s/  Perry  Smith               Date:  December 24, 2002
                       ---------------------------             -----------------
                       Perry Smith
                       President and Director


                   By:  /s/  Dean  Branconnier          Date:  December 24, 2002
                       ---------------------------             -----------------
                        Dean Branconnier
                        Vice President and Director


                   By:  /s/  Chad  Burback              Date:  December 24, 2002
                       ---------------------------             -----------------
                        Chad Burback
                        Secretary and Director


                                       20
<PAGE>
<TABLE>
<CAPTION>
                          INDEX TO FINANCIAL STATEMENTS

<S>                                                                         <C>
Independent Auditor's Report . . . . . . . . . . . . . . . . . . . . . . .  F-1

Balance Sheet as at September 30, 2002 . . . . . . . . . . . . . . . . . .  F-2

Statements of Operations for the year ended September 30, 2002,
September 30, 2001, the nine months ended September 30, 2000,
and the period from September 15, 1995 (inception) to September 30, 2002 .  F-3

Statements of Stockholders Equity for the year ended September 30, 2002,
September 30, 2001, the nine months ended September 30, 2000,
and the period from September 15, 1995 (inception) to September 30, 2002 .  F-4

Statement of Cash Flow for the year ended September 30, 2002,
September 30, 2001, the nine months ended September 30, 2000,
and the period from September 15, 1995 (inception) to September 30, 2002 .  F-5

Notes to Financial Statements. . . . . . . . . . . . . . . . . . . . . . .  F-6
</TABLE>


<PAGE>
To the Board of Directors and Shareholders
Duro Enzyme Products Inc.
Langley, British, Columbia

                          INDEPENDENT AUDITOR'S REPORT

I  have  audited  the  balance sheet of Duro Enzyme Products Inc. (Formerly Home
Web,  Incorporated) (a development stage company) as of September 30, 2002, 2001
and 2000 and the related statements of operations, stockholders' equity and cash
flows  for  the  year  ended  September 30, 2002, 2001 and the nine month period
ended  September  30, 2000. These financial statements are the responsibility of
the  Company's  management.  My responsibility is to express an opinion on these
financial  statements  based  on  my  audit.

I conducted my audit in accordance with generally accepted auditing standards of
the United States.  Those standards require that I plan and perform the audit to
obtain  reasonable  assurance about whether the financial statements are free of
material  misstatement.  An  audit includes examining, on a test basis, evidence
supporting  the  amounts  and  assessing  the  accounting  principles  used  and
significant  estimates  made  by  management,  as well as evaluating the overall
financial  statement  presentation.  I believe that my audit provides reasonable
basis  for  my  opinion.

The  accumulated  deficit  from  the  date of inception to September 30, 2002 is
$7,089,548.

In  my  opinion,  the  financial  statements  referred to in the first paragraph
present  fairly, in all material respects, the financial position of Duro Enzyme
Products Inc (Formerly Home Web, Incorporated) (A Development Stage Company), as
of  September  30,  2002,  2001  and 2000 and the results of operations the cash
flows and the cumulative results of operations and cumulative cash flows for the
year  then  ended in conformity with generally accepted accounting principles of
the  United  States.

The  accompanying  financial  statements have been prepared assuming the Company
will  continue  as  a  going  concern.  As discussed in Note 14 to the financial
statements,  the  Company  has  incurred net losses since inception, which raise
substantial  doubt  about  its  ability  to  continue  as  a going concern.  The
financial  statements  do  not include any adjustment that might result from the
outcome  of  this  uncertainty.


/s/  "Hawkins  Accounting"

DECEMBER  23,  2002


                                       F-1
<PAGE>
<TABLE>
<CAPTION>
                                DURO ENZYME PRODUCTS, INCORPORATED
                                       (FORMERLY HOME WEB)
                                  (A Development Stage Company)
                                    CONSOLIDATED BALANCE SHEET
                                 September 30, 2002, 2001 and 2000


ASSETS
                                                            2002          2001          2000
                                                        ------------  ------------  ------------
<S>                                                     <C>           <C>           <C>
Current assets
  Cash in bank                                          $    (1,262)  $     3,189   $         0
  Non-trade receivable                                      102,163            70         1,450
                                                        ------------  ------------  ------------
    Total current assets                                    100,901         3,259         1,450
Equipment
  Coolers and equipment                                                                  40,308
  Office equipment                                                                        9,841
                                                        ------------  ------------  ------------
                                                                  0             0        50,149
  Accumulated depreciation                                                               (9,288)
                                                        ------------  ------------  ------------
    Total equipment                                               0             0        40,861
Other assets
  Trade name                                                                             11,000
  Licenses (net)                                          2,000,000     2,250,000
                                                        ------------  ------------  ------------
    Total other assets                                    2,000,000     2,250,000        11,000
                                                        ------------  ------------  ------------
TOTAL ASSETS                                            $ 2,100,901   $ 2,253,259   $    53,311
                                                        ============  ============  ============

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
  Accounts payable and fees                             $ 1,601,259   $   153,383   $     1,426
  Short term notes                                          447,249       107,833        25,962
                                                        ------------  ------------  ------------
    Total current liabilities                             2,048,508       261,216        27,388

Net Liabilities of Subsidiary disposesed                     12,777             0             0
Long term debt                                            2,752,738     2,627,740             0
                                                        ------------  ------------  ------------
TOTAL LIABILITIES                                         4,814,023     2,888,956        27,388
Shareholders' equity
  Preferred stock, 40,000,000 shares authorized $.001
    par value, 0 shares outstanding                               0             0             0
  Common stock, 3,200,000,000 authorized, $.001 par
  value, 657,778,000 outstanding                             87,757        27,507        27,507
  Paid in capital                                         4,288,669     1,347,493     1,347,493
  Deficit accumulated during development stage           (7,089,548)   (2,010,697)   (1,349,077)
                                                        ------------  ------------  ------------
    Total shareholders' equity                           (2,713,122)     (635,697)       25,923
                                                        ------------  ------------  ------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY              $ 2,100,901   $ 2,253,259   $    53,311
                                                        ============  ============  ============
</TABLE>

    The accompanying notes are an integral part of the financial statements

                                       F-2
<PAGE>
<TABLE>
<CAPTION>
                               DURO ENZYME PRODUCTS, INCORPORATED
                                      (FORMERLY HOME WEB)
                                 (A Development Stage Company)
                              CONSOLIDATED STATEMENT OF OPERATIONS
                       For the year ended September 30, 2002, 2001 and the
                              nine months ended September 30, 2000


                                                                                        Deficit
                                                                                      Accumulated
                                                                                        During
                                                                                      Development
                                           2002           2001           2000           Stage
                                       -------------  -------------  -------------  -------------
<S>                                    <C>            <C>            <C>            <C>
Sales                                  $          0   $          0   $          0   $     18,887
Cost of Sales                                     0              0              0         15,091
                                       -------------  -------------  -------------  -------------
Gross Margin                                      0              0              0          3,796
Expenses
  Advertising                                   331                                        1,187
  Amortization                              250,000        250,000                       510,872
  Consulting and professional fees          597,667        195,406          2,929        807,198
  Office and administration                 424,037          1,724             70        445,405
  Investor communication                      3,232          5,706                         8,938
  Travel, meals and entertainment             2,672          8,567                        13,918
  Rent, utilities and telephone             239,990         36,000                       279,581
  Research and Development                  411,051                                      411,051
  Organization and start up costs                                                         41,674
  Compensation due stock issuance                                                      1,254,500
                                       -------------  -------------  -------------  -------------
    Total expenses                        1,928,980        497,403          2,999      3,774,324
                                       -------------  -------------  -------------  -------------
    (Loss) from operations               (1,928,980)      (497,403)        (2,999)    (3,770,528)
Other income (expense)
  Loss on asset write-off                (3,083,000)       (53,311)                   (3,136,361)
  Interest                                 (137,094)      (134,354)                     (272,330)
  Recovery of accounts payable                    0         27,380                        27,380
  State tax expense                                                          (800)        (4,000)
                                       -------------  -------------  -------------  -------------
    Total other expenses                 (3,220,094)      (160,285)          -800     (3,385,311)
                                       -------------  -------------  -------------  -------------
  Loss before discontinued operation     (5,149,074)      (657,688)        (3,799)    (7,155,839)
    Loss on discontinued operations         (12,777)             0              0        (12,777)
                                       -------------  -------------  -------------  -------------
    Net Loss                           $ (5,161,851)  $   (657,688)  $     (3,799)  $ (7,168,616)
                                       =============  =============  =============  =============
Loss per share
  of common stock                      $      (0.01)  $      (0.01)  $      (0.01)  $      (0.01)
Weighted average of
  shares outstanding                    657,778,000    657,528,000    657,528,000    657,528,000
                                       =============  =============  =============  =============
</TABLE>

    The accompanying notes are an integral part of the financial statements

                                       F-3
<PAGE>
<TABLE>
<CAPTION>
                                    DURO ENZYME PRODUCTS INCORPORATED
                                           (FORMERLY HOME WEB)
                                      (A Development Stage Company)
                             CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY
                        For the year ended September 30, 2002, 2001 and for the
                                  nine months ended September 30, 2000


                                              2000
                                              ----
                                                                       Deficit
                                    Common stock                     Accumulated
                             --------------------------                During
                                                          Paid in    Development
                                Shares        Amount      Capital       Stage         Total
                             ------------  ------------  ----------  ------------  ------------
<S>                          <C>           <C>           <C>         <C>           <C>
Balance,
   December 31, 1999          27,507,000   $    27,507   $1,347,493  $(1,345,278)  $    29,722
February 23, 2000,
 forward stock split           5,369,400
Net loss for the period
   ended September 30, 2000                                               (3,799)       (3,799)
                             ------------  ------------  ----------  ------------  ------------
                              32,876,400   $    27,507   $1,347,493  $(1,349,077)  $    25,923
                             ============  ============  ==========  ============  ============


                                              2001
                                              ----
Balance
   September 30, 2000         32,876,400   $    27,507   $1,347,493  $(1,349,077)  $    25,923
Consolidation of subsidiary                                               (3,932)       (3,932)
Net loss for the year
   ended September 30, 2001                                             (657,688)     (657,688)
                             ------------  ------------  ----------  ------------  ------------
                              32,876,400   $    27,507   $1,347,493  $(2,010,697)  $  (635,697)
                             ============  ============  ==========  ============  ============

                                              2002
                                              ----
Balance
   September 30, 2000         32,876,400   $    27,507   $1,347,493  $(2,010,697)  $  (635,697)
March 4, 2002
 forward stock split         624,651,600
Issuance of option stock         250,000           250        1,175                      1,425
Purchase of Business          60,000,000        60,000    2,940,001       83,000     3,083,001
Shares not issued            (60,000,000)                                                    0
Net loss for the year
   ended September 30, 2002                                           (5,161,851)   (5,161,851)
                             ------------  ------------  ----------  ------------  ------------
                             657,778,000   $    87,757   $4,288,669  $(7,089,548)  $(2,713,122)
                             ============  ============  ==========  ============  ============
</TABLE>

    The accompanying notes are an integral part of the financial statements

                                       F-4
<PAGE>
<TABLE>
<CAPTION>
                                      DURO ENZYME PRODUCTS INCORPORATED
                                             (FORMERLY HOME WEB)
                                        (A Development Stage Company)
                            CONSOLIDATED STATEMENT OF CASH FLOWS-INDIRECT METHOD
                            For the year ended September 30, 2002, 2001 and the
                                    nine months ended September 30, 2000


                                                                                                     Cash flows
                                                                                                    Accumulated
                                                                                                      During
                                                                                                    Development
                                                               2002          2001         2000         Stage
                                                           -------------  -----------  -----------  ------------
<S>                                                        <C>            <C>          <C>          <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)                                          $ (5,161,851)  $ (657,688)  $   (3,799)  $(2,006,765)
Adjustments to reconcile net income to net cash
  provided by operating activities
  Depreciation and amortization                                 250,000      250,000                    259,288
  Stock issued for services                                                                           1,254,500
  Expensing of organization costs                                                                         2,366
  Increase in accounts payable                                1,447,876      153,383                    153,383
  Increase in accounts receivable                              (102,093)         (70)                    (1,520)
  Recovery from accounts payable                                      0      (27,388)                   (27,388)
  Loss on disposal of assets, writedowns                      3,083,000       53,311                     53,311
  Increase in Assets to be disposesed                            12,777
  Increase in accrued liabilities                                                           3,792        27,888
                                                           -------------  -----------  -----------  ------------
NET CASH PROVIDED BY OPERATING
  ACTIVITIES                                                   (470,291)    (228,452)          (7)     (284,937)
INVESTING ACTIVITIES
  Increase in other assets                                                                               13,366
  Purchase of license                                                 0    2,500,000                  2,500,000
  Purchase of equipment                                       3,000,000                                  50,149
                                                           -------------  -----------  -----------  ------------
NET CASH USED IN INVESTING ACTIVITIES                         3,000,000    2,500,000                  2,563,515
FINANCING ACTIVITIES
  Sale of common stock                                           61,425                                 120,000
  Retained earnings of subsidiary                                     0       (3,932)                    (3,932)
  Increase in paid in capital                                 2,940,001
  Long term debt                                                124,998    2,627,740                  2,627,740
  Short term notes                                              339,416      107,833                    107,833
                                                           -------------  -----------  -----------  ------------
NET CASH GENERATED FROM FINANCING ACTIVITIES                  3,465,840    2,731,641                  2,851,641
INCREASE (DECREASE) IN CASH AND CASH
  EQUIVALENTS                                                    (4,451)       3,189           (7)        3,189
Cash and cash equivalents at the beginning of the period          3,189            0            7             0
                                                           -------------  -----------  -----------  ------------
CASH AND CASH EQUIVALENTS AT THE END OF
  THE PERIOD                                               $     (1,262)  $    3,189   $        0   $     3,189
                                                           =============  ===========  ===========  ============
</TABLE>

    The accompanying notes are an integral part of the financial statements


                                       F-5
<PAGE>
                       DURO ENZYME PRODUCTS, INCORPORATED
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                        SEPTEMBER 30, 2002, 2001 AND 2000


NOTE  1:     SIGNIFICANT  ACCOUNTING  POLICIES
             ---------------------------------

Nature  of  business
--------------------
     Duro  Enzyme Products, Inc. (the Company) and its wholly owned subsidiaries
     are acquiring revenue generating businesses that will enable the Company to
     apply  its licensed stable enzyme technologies to generate revenues to fund
     the  pursuit  of the current business plan. Subsequent to the Balance Sheet
     date  the  Company  ceased  its  research activities into the stable enzyme
     technology  and  disposed a subsidiary. The Company is actively seeking new
     areas  of  business  and  has  several  potential  acquisitions.

Name  change
------------
     The  Company  was  incorporated  under  the  laws of the State of Nevada on
     September  15,  1995.  The  Company was originally formed to sell wholesale
     gourmet  and specialty cheese on the internet. On October 16, 2000 a merger
     was  completed with a private company (Duro Enzyme Products, Inc.) in which
     shares  were  exchanged  one  for  28,800,000.  As  a  result  of the share
     exchange, the shareholders of Duro Enzyme Products Inc. became the majority
     shareholders  of  the  common  stock of the Company. The Company's name was
     formally  changes  to  Duro  Enzyme Products, Inc. on February 5, 2001 at a
     special  shareholders  meeting.  The  accounting  year  was  changed from a
     December  31  year-end  to  a  September  30  year-end.

Development  Stage  Company
---------------------------
     The  Company  is  a  development  stage company as defined in the Financial
     Accounting Standards Board No. 7. The Company is devoting substantially all
     of  its  present  efforts  in securing and establishing a new business, and
     although  planned principal operations have commenced, substantial revenues
     have  yet  to  be  realized.

Use  of  estimates
------------------
     The  preparation  of  the financial statements in conformity with generally
     accepted  accounting  principles of the United States require management to
     make  estimates and assumptions that affect the reported amounts of assets,
     liabilities  and  disclosures  of contingent liabilities at the date of the
     financial  statements  and  the  reported  amounts of revenues and expenses
     during  the reporting period. Accordingly, actual results could differ from
     these  estimates.

Principles  of  Consolidation
-----------------------------
     The  consolidated  financial statements include the accounts of Duro Enzyme
     Products,  Inc.  and  its  wholly  owned  subsidiaries:
          Duro  Enzyme  Solutions,  Inc-Nevada,  USA
          Duro  Enzyme  Solutions,  Inc-British  Columbia  Canada


                                      F-6
<PAGE>
                       DURO ENZYME PRODUCTS, INCORPORATED
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                        SEPTEMBER 30, 2002, 2001 AND 2000


NOTE  1:     SIGNIFICANT  ACCOUNTING  POLICIES  (CON'T)
             ------------------------------------------

     During  the  period  the  Company  purchased  all the outstanding shares of
     Bruden  Steaming  and Vac Truck Services Ltd. The transaction was accounted
     for  by  the  purchase  method  of  accounting  for  business combinations.

     Prior  to  year end, the business was disposed of and the results of Bruden
     Steaming  and  Vac  Truck  Services  Ltd. during the period are included as
     discontinued  operations  in  the  financial  statements.  All  material
     transactions  have  been  eliminated.

Cash  equivalents
-----------------
     For  the  purpose of the statement of cash flows, the company considers all
     highly  liquid  debt  instruments  purchased  with the original maturity of
     three  months  or  less  to  be  cash  equivalents.

Property  and  equipment
------------------------
     Property  and  equipment  are recorded at cost. Maintenance and repairs are
     expensed  as incurred; major renewals and betterments are capitalized. When
     items  of  property or equipment are sold or retired, the related costs and
     accumulated depreciation are removed from the accounts and any gain or loss
     is included in income. Depreciation is provided using the straight line and
     accelerated  methods  over  the useful lives provided by statute, including
     the election to expense the cost of property acquisitions in certain years.

Intangible  and  other  assets
------------------------------
     The  cost  of purchase of other assets is recorded at the purchase price of
     the  contract  and  amortized  over  its useful life not to exceed 10 years
     using  the straight-line method. Amortization cost for year ended September
     30,  2002  and  2001  is  $250,000  each  year.

Income  Taxes
-------------
     Income  taxes  are provided for the tax effects of transactions reported in
     the  financial  statements and consist of taxes currently due plus deferred
     taxes  related primarily to differences between the recorded book basis and
     tax basis of assets and liabilities for financial and income tax reporting.
     The  deferred  tax  assets  and liabilities represent the future tax return
     consequences  of  those  differences,  which  will  either  be  taxable  or
     deductible  when  the  assets  and  liabilities  are  recovered  or settle.
     Deferred  taxes are also recognized for operating losses that are available
     to  offset  future  taxable  income  and  tax credits that are available to
     offset  future  federal  income  taxes.


                                      F-7
<PAGE>
                       DURO ENZYME PRODUCTS, INCORPORATED
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                        SEPTEMBER 30, 2002, 2001 AND 2000


NOTE  1:     SIGNIFICANT  ACCOUNTING  POLICIES  (CON'T)
             ------------------------------------------

Comprehensive  Income
---------------------
     Generally  accepted  accounting  principles  require  the  inclusion of the
     statement  of  Comprehensive Income for certain transactions involving gain
     or  loss  on  foreign  currency transactions. No Statement of Comprehensive
     Income  has been prepared since the activity involving the subsidiary, Duro
     Enzyme  Solution  Inc.,  British  Columbia,  Canada,  is  immaterial

NOTE  2:     LOSS  ON  DISPOSAL  OF  ASSETS
             ------------------------------

     Pursuant to the decision made by the board of directors to change the focus
     of  the  company  from the sale of gourmet food and specialty cheese on the
     internet  to the Research and development of the license and manufacture of
     unique  stable and natural enzymes and specialty end products the equipment
     and  trade  name  that was used to promote the sale of the gourmet food and
     specialty  cheese  was  abandoned.  The  management of the Company made the
     decision  to  recognize  the  loss  for the year ending September 30, 2001.

NOTE  3:     LICENSE
             -------

     In  September  2000,  the  Company,  through  its  subsidiary  Duro  Enzyme
     Solutions,  Inc.  Nevada,  USA,  entered  into  a  License and Distribution
     Agreement  to  use  exclusive  stable  enzyme  production  technology, both
     current  and further developed by the Company from its own research for the
     term of the agreement. The purchase price of this license is $2,500,000 and
     was  satisfied  by  a  promissory note bearing interest at a rate of 5% per
     annum  which  does  not  commence  until  the Company begins selling stable
     enzymes.  At that time, the Company is obligated to pay, within five years,
     the  principal  amount  and any accrued interest. Interest will continue to
     accrue  throughout  the term of the note. Royalty payments equal to 2.5% of
     gross  revenue  generated  by  the  Company  from  use  of  the  licensed
     technologies  will  be  paid  by  the  Company  on  a  quarterly basis. The
     $2,500,000 is being amortized over a 10-year period using the straight-line
     method.  This  License  is  with  a  related  party.  See  note  4.

NOTE  4:     RELATED  PARTY  TRANSACTION
             ---------------------------

          A  total  of  $183,685 was accrued in consultant services for the year
     ending  September  30,  2002  and  $120,000  September  30, 2001. The total
     outstanding  and  unpaid is $333,685 at September 30, 2002 and was $150,000
     at September 30, 2001. Eleven (11) companies, which are owned or controlled
     by  shareholders  or  creditors  of the Company, have provided services and
     expertise  to  the  Company  during  this  period.

                                      F-8
<PAGE>
                       DURO ENZYME PRODUCTS, INCORPORATED
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                        SEPTEMBER 30, 2002, 2001 AND 2000


NOTE  4:     RELATED  PARTY  TRANSACTION  (CON'T)
             ------------------------------------

     During the year ended September 30, 2001, the Company endorsed Research and
     Development  Service  Agreements  with a company owned by a creditor of the
     Company.  This  agreement  retains  the  Founder's  company's expertise and
     services  for  research,  development, design, and related consultations. A
     consulting  fee  is  charged  at  a  standard  rate,  established  by  the
     consultants.  An  additional  15%  is  charged  on  incurred  costs  as  an
     administrative,  overhead  and  handling  charge.  The  initial term of the
     Agreements  dated  is  five  consecutive  years.  All  successive  renewals
     effective  automatically  with the lapse of the current term. The long-term
     debt  owed  is  also  owed  to the creditor in the amount of $2,752,738. At
     September  30,  2001  the  amount  owed  was  $2,627,740.

     Short-term  loans  of  $339,416  were  advanced  to  the  Company  by three
     shareholders  during  the  year  ending  September  30,  2002.  $81,871 was
     advanced  during the year ended September 30, 2001. The funds were used for
     operating  capital.

     The  Company  has two 5-year leases for facilities. One lease is for office
     space  and furnishings. This lease has accrued rent at the end of September
     30,  2002,  of  $176,612, $36,000 at September 30, 2001. The other lease is
     for  Research  space. It has accrued rent at the end of September 30, 2002,
     of  $120,168,  $NIL  at  September  30,  2001.  Both  leases  are  held  by
     shareholders  of  the  Company,  who  own  the  premises. Subsequent to the
     year-end  the  lease was terminated for the main office as a new owner took
     over  the  building. The Company is in the process of negotiating new terms
     for  the  space  and  anticipates  lowering  the  rental  costs.

     The  Company  has  accrued  fees  of  $572,228  to September 30, 2002 for a
     36-month  Technology,  Operations,  Maintenance,  Research  &  Development,
     Engineering  and  Training  consulting  contract  with  a  company owned by
     shareholders.  The contract was entered into on January 1, 2002. Subsequent
     to  the  Balance Sheet the contract was canceled and both parties agreed to
     repay  the  outstanding  fees  from  revenue  generated  by  the  Company.

     The  Company  has  accrued  fees  of  $126,692 to September 30, 2002, for a
     4-month  Office,  Accounting & Administration contract with a company owned
     by  shareholders who own less than 5% of DEPI authorized and issued shares.
     The  Company  entered into the contract for the period of time necessary to
     prepare its in-house office, accounting, and administrative department. The
     duration  of  the  contact  was  from  January  1, 2002, to April 30, 2002.
     Subsequent  to  the  Balance  Sheet  date  both parties agreed to repay the
     outstanding  fees  from  revenue  generated  by  the  Company.


                                      F-9
<PAGE>
                       DURO ENZYME PRODUCTS, INCORPORATED
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                        SEPTEMBER 30, 2002, 2001 AND 2000


NOTE  4:     RELATED  PARTY  TRANSACTION  (CON'T)
             ------------------------------------

     The  Company  issued  250,000  common  shared to a director of the Company,
     which  were  paid  by  a  reduction  of  Consulting  Fees  of  $15,000.

     During the period ending September 30, 2000, an affiliated company advanced
     the Company $20,908. This money was used to pay off the accounts payable as
     of  June  30,  2000.

NOTE  5:     INCOME  TAXES
             -------------

     The  benefit  for  income  taxes from operations consisted of the following
     components:  current  tax  benefit  of  $234,000  for  September  30,  2002
     resulting from a net loss before income taxes, and deferred tax expenses of
     $  234,000  resulting  from  a  valuation  allowance  recorded  against the
     deferred  tax asset resulting from net operating losses. Net operating loss
     carryforward  will  expire  in  2013.

     The  valuation  allowance  will  be  evaluated  at  the  end  of each year,
     considering  positive and negative evidence about whether the asset will be
     realized.  At  the time, the allowance will either be increased or reduced;
     reduction  would  result  in  the  complete elimination of the allowance if
     positive  evidence indicates that the value of the deferred tax asset is no
     longer  required.

     No  provision  is  being  made  for  state  income  tax for the year ending
     September  30,  2002 since all operations are in Canada. In prior years the
     operations  were  in  California  and  California  Franchise  taxes  were
     applicable.

NOTE  6:     COMMON  STOCK
             -------------

     On  February  10,  2000  the board of directors voted a 1.2:1 forward stock
     split  as  of  the  record  date  of  February  23,  2000.

     On January 31, 2002 the board of directors voted a 20:1 forward stock split
     as  of  the  record  date  March  4,  2002.

     On  April  18,  2002  the  board approved the issuance of 250,000 shares to
     James  C.  Florio,  for  his  ongoing assistance to the board of Directors.

     On  May  29,  2002 the Company acquired a new business, Bruden Steaming and
     Vac  Truck  Services  Ltd.  "(Bruden"). In exchange for all the outstanding
     shares  of Bruden the Company issued 60,000,000 common shares. On September
     30,  2002


                                      F-10
<PAGE>
                       DURO ENZYME PRODUCTS, INCORPORATED
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                        SEPTEMBER 30, 2002, 2001 AND 2000


NOTE  6:     COMMON  STOCK  (CON'T)
             ----------------------

     the board of directors agreed to review the disposal of Bruden subject to a
     review  of  its  financial  statements.  On  December 23, 2002 the board of
     Directors  agreed  to  dispose  of Bruden in exchange for the return of the
     60,000,000  common  shares  of  the  Company.

NOTE  7:     FIXED  ASSETS
             -------------

     The  Company's  only  Fixed assets were part of the Company Bruden Steaming
     and  Vac Truck Services Ltd. as a result of the disposition on December 23,
     2002  the  assets  have  been  disclosed  as part of the Net Liabilities of
     Bruden  and  as  of  December  23,  2002,  it  has no further Fixed assets.

     For  the  year  ending  September  30, 2002, 2001 and 2000 depreciation was
     $79,321,  $0  and  $1,321  respectively.

NOTE  8:     NOTES  PAYABLE
             --------------

     Note  payable  annual interest of 5% per annum. Note is tied to purchase of
     the license agreement. Payment terms are tied to the commencing of sales by
     the Company. Interest accrues until such time as six months from first date
     of sales. At such time, principal plus accrued interest will be repaid over
     five  years.

     Short term borrowings are from related parties and are discussed in Note 4.

NOTE  9:     EARNINGS  PER  SHARE
             --------------------

     Basic  earnings  per  share  are computed by dividing earnings available to
     common  stockholders  by  the  weighted  average  number  of  common shares
     outstanding during the period. Diluted earnings per share reflect per share
     amounts  that  would have resulted if resulted if dilutive potential common
     stock  had been converted to common stock. The following reconciles amounts
     reported  in  the  financial  statements.


                                               For the Nine Months Ended 2000
                                        ----------------------------------------
                                            Income         Shares      Per-Share
                                          (Numerator)   (Denominator)    Amount
                                        --------------  ------------------------
     Income  from  continuing  operations
      available  to  common  stockholders
      basic  earnings  per  share           $ (3,799)     657,778,000  $  (.001)
                                                                       =========


                                      F-11
<PAGE>
                       DURO ENZYME PRODUCTS, INCORPORATED
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                        SEPTEMBER 30, 2002, 2001 AND 2000


NOTE  9:     EARNINGS  PER  SHARE  (CON'T)
             -----------------------------

                                               For the Nine Months Ended 2001
                                        ----------------------------------------
                                            Income         Shares      Per-Share
                                          (Numerator)   (Denominator)    Amount
                                        --------------  ------------------------
Income  from  continuing  operations
 available  to  common  stockholders
 basic  earnings  per  share               $(657,688)     657,778,000   $  (.01)
                                                                       =========


                                               For the Nine Months Ended 2002
                                        ----------------------------------------
                                            Income         Shares      Per-Share
                                          (Numerator)   (Denominator)    Amount
                                        --------------  ------------------------
Income  from  continuing  operations
 available  to  common  stockholders
 basic  earnings  per  share             $(5,161,851)     657,778,000    $(.01)
                                                                       =========


NOTE  11:     LEASES
              ------

     The  Company has two five-year leases, one for office space and furnishings
     and  the  other for research facilities. A total of $239,990 was charged to
     rent  expense under these leases during the year ending September 30, 2002.
     These  leases  are  recorded as an operating lease and the amounts paid are
     charged  to  expense.  The  Company  has three successive five year renewal
     options  for  the research facilities lease. It is expected in the ordinary
     course of business that the Company will renew the research facility leases
     at  the  present  location.  Subsequent  to  the  year-end  the  lease  was
     terminated  for  the main office as a new owner took over the building. The
     Company  is  in  the  process  of  negotiating  new terms for the space and
     anticipates  lowering  the  rental  costs.  The  Company has terminated its
     Research operations subsequent to the Balance Sheet date and is looking for
     alternative  uses  for  the  Research  facility  leased  space.

     The  Company  is  committed  under  its  lease to December 31, 2006. Future
     minimum  annual  lease  payments  are  due  as  follows:

               Year                 Amount
               ----                 --------
               2003                 $160,224
               2004                 $160,224
               2005                 $160,224
               2006                 $160,224
               2007                 $40,056.


                                      F-12
<PAGE>
                       DURO ENZYME PRODUCTS, INCORPORATED
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                        SEPTEMBER 30, 2002, 2001 AND 2000


NOTE  12:     ACQUISITION  AND  DISPOSITION
              -----------------------------

     On  May  29,  2002  the Company acquired all of the outstanding shares of a
     private  company,  Bruden  Steaming and Vac Truck Services Ltd. ("Bruden").
     The  results  of Bruden's operations have been included in the consolidated
     financial  statements  as  loss  on discontinued operations. The total loss
     incurred  during  the period May 29, 2002 to September 30, 2002 is $12,777.
     On  September  27, 2002 the Board of Directors of the Corporation agreed to
     review  the  purchase  and  the  Financial Statements of Bruden. Management
     determined  that  the entire amount of Goodwill obtained in the purchase of
     Bruden  should be adjusted to zero. In accordance with Financial Accounting
     Statement  number  144,  the  goodwill  needs  to  be adjusted prior to any
     computation  of  a  gain or loss on the disposal of Bruden. On December 23,
     2002  Management  agreed  to dispose of Bruden. Bruden has been included in
     discontinued  operations and its net liabilities of $12,777 included on the
     Balance  Sheet. This computation of gain or loss on the sale of Bruden will
     be  included  in  the  following  periods  results.

     The  aggregate  purchase price was 60,000,000 shares of common stock of the
     Company.  The  value  of the 60,000,000 common shares issued was determined
     based  on  the  average  market  price of Duro's common shares over a 2-day
     period  before  and  after  the  date  of  the  acquisition.


                                      F-13
<PAGE>
                       DURO ENZYME PRODUCTS, INCORPORATED
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                        SEPTEMBER 30, 2002, 2001 AND 2000


NOTE  12:     ACQUISITION  AND  DISPOSITION  (CON'T)
              --------------------------------------

     The  following  table  summarizes  the  estimated  fair value of the assets
     acquired and liabilities assumed at the date of acquisition. Duro is in the
     process  of  valuing goodwill, thus the allocation of the purchase price is
     subject  to  refinement.

     Current  assets                      $  101,142
     Fixed  assets                           542,789
     Goodwill                              3,083,000
                                          -----------
     Total  assets  acquired               3,726,931
     Current  liabilities                   (165,415)
     Long  term  debt                       (561,516)
                                          -----------
     Total  liabilities  assumed            (726,931)
     Net  assets  acquired                $3,000,000
                                          ===========

NOTE  13:     SEGMENT  INFORMATION
              --------------------

     All revenue for the year ending September 30, 2002 was derived from Bruden.
     Bruden  has  been  disposed  of  on  December  23,  2002.

NOTE  14:     GOING  CONCERN
              --------------

     As  of  September  30,  2002,  the  Company  had  net losses from operating
     activities,  which raise substantial doubt about its ability to continue as
     a  going  concern.

     The  Company  plans  to  acquire new business and raise funds, through debt
     issuance  or  through  the  generation  of revenue and achieving profitable
     operations.  It  will  also  continue  to  pursue  acquisitions  and  joint
     ventures,  to  strengthen  both  its  balance  sheet  and  cash-flow.

     Subsequent to the Balance Sheet date the Company has been actively pursuing
     new  acquisitions.  Currently  the  Company  is  negotiating  with  several
     potential  businesses that would significantly change the operations of the
     Company.

     The  Company's  ability  to  continue  as a going concern is dependent upon
     raising capital through debt financing and ultimately by generating revenue
     and achieving profitable operations. There is no assurance that the Company
     will  be  successful in its efforts to raise additional proceeds or achieve
     profitable  operations.  The  financial  statements  do  not  include  any
     adjustments  that  might  result  from  the  outcome  of  this uncertainty.


                                      F-14
<PAGE>
                       DURO ENZYME PRODUCTS, INCORPORATED
                               (FORMERLY HOME WEB)
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS
                        SEPTEMBER 30, 2002, 2001 AND 2000


NOTE  15:     SUBSEQUENT  EVENTS
              ------------------

     Subsequent  to  the  Balance  Sheet  date  the Company shut down its enzyme
     research.  Several  of the Company's contracts have been amended due to the
     change  in  the  operation  of  the  business.  These actions were taken as
     management considers its future use of the enzyme technology. Management is
     also  considering  the  sale  of the technology and is in discussions about
     this.  It  is  highly  likely  that  the  operations  of  the  Company will
     significantly  change.


                                      F-15
<PAGE>
                                  EXHIBIT INDEX

EXHIBIT
NUMBER     DESCRIPTION
------     -----------
3.1****    Amended  and  Restated Articles of Incorporation dated February 5,
           2001

3.2****    Amended  and  Restated  Bylaws  dated  January  8,  2001

4.1**      Specimen Stock Certificate for Shares of Common Stock of the Company

10.1*****  Lease  Agreement  dated  December  12,  2001

10.2***    License  and  Distribution  Agreement between 529473 B.C. Ltd. and
           Duro Enzyme  Solutions  Inc.  (U.S.), as amended, dated September 22,
           2000

10.3*      Research and Development Services Agreement between 529473 B.C. Ltd.
           and Duro  Enzyme Solutions Inc. (Canada), as amended, dated September
           21,  2000

10.4*      Research and Development Services Agreement between 529473 B.C.
           Ltd.  and  Duro  Enzyme  Solutions Inc. (U.S.), as amended, dated
           September  21,  2000


16.1*****  Letter  from  BDO  Dunwoody,  Chartered Accountants, to the U.S.
           Securities  and  Exchange  Commission

16.2*****  Letter  from  Raber  Mattuck, Chartered Accountants, to the U.S.
           Securities  and  Exchange  Commission

21.1       List of Subsidiaries

23.0       Consent Letter

*  Filed  on  November  20,  2000, as an exhibit to the Company's report on Form
10-QSB  for the three months ended September 30, 2000 and incorporated herein by
reference
**  Filed  on  December  29,  2000,  as an exhibit to the Company's transitional
report  on  Form  10-KSB  for  the  nine  months  ended  September  30, 2000 and
incorporated  herein  by  reference
***  Filed  on  February 14, 2001, as an exhibit to the Company's report on Form
10-QSB  for  the three months ended December 31, 2000 and incorporated herein by
reference.
**** Filed on May 15, 2001, as an exhibit to the Company's report on Form 10-QSB
for the three months ended March 31, 2001, and incorporated herein by reference.
*****  Filed on December 29, 2001, as an exhibit to the Company's report on Form
10-KSB  for  the  year  ended  September  30,  2001,  and incorporated herein by
reference.


<PAGE>